Ann: Quarterly Update and Appendix 4C, page-7

First 7 Last

Share
Profile

Follow
Akki

35,790 Posts.

555

27/10/17

21:19

Post #: 28270014
Share

Originally posted by SoT ↑

Some things that stood out for me:
- SU talked about the granted patent for phylomers that have the ability to enter specific brain cells. She said this shows that PYC libraries have certain peptides that are 'cell specific'. That enables PYC to target high value cells.
- Getting good results with Stat5 program. Good binding.
- They are looking to engineer FPPs to target particular cargoes and improve their performance for different job characteristics. So to give commercialisation opportunities, to set PYC up for the future.
- The in-vivo (live animal model) results in the first half of 2018 will be over a range of cargoes, not just PYC's own programs. The first set will be iMyc.
- RH said that they are moving forward with different experiments. Some to validate the FPPs others to validate iMyc. They have some 'beautiful' data on the function of their FPPs that shows very nicely that it works. It should be published soon. The journal sent the paper back for some minor additions to the manuscript.
- RK left due to commitments with Kite Pharma following Gilead takeover.
- SU said PYC are moving to more commercial phase so SN is a good fit.
- SU confident there is sufficent cash till end of 2018.
- Over reliance on Q&A of which only one question was asked.
Anyone feel free to add.

Expand

Not sure how they figure their cash will last them until the end of 2018 unless they are making some dart board predictions they will find a deal ?

Down to $4m cash by xmas and even using old old figures of $1.5m a quarter that’s less than 3.

I’ll punt on unless they’ve signed a deal by end of Q1 2018 they tap for cash.

Last edited by Akki: 27/10/17

PYC Price at posting: 3.8¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

NEU

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 7 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.25		Change -0.035(2.72%)		Mkt cap ! $729.0M

Open	High	Low	Value	Volume
$1.29	$1.29	$1.25	$4.615M	3.648M

Buyers (Bids)

No.	Vol.	Price($)
1	19679	$1.25

Sellers (Offers)

Price($)	Vol.	No.
$1.27	17771	6

View Market Depth

No.	Vol.	Price($)
1	19780	1.250
1	11669	1.230
2	4225	1.225
1	20000	1.220
1	4000	1.200

Price($)	Vol.	No.
1.270	17771	6
1.285	58876	2
1.295	24500	1
1.300	28670	3
1.325	9001	1

Last trade - 14.42pm 26/06/2025 (20 minute delay)

PYC (ASX) Chart

Ann: Quarterly Update and Appendix 4C, page-7

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Update and Appendix 4C, page-7

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up

Neuren jumps over +11% on patent win for Pitt Hopkins drug treatment

Thursday's HotCopper trends: Paradigm's drug IP buy, MTM placement | June 26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News